DE60234085D1 - Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor - Google Patents

Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor

Info

Publication number
DE60234085D1
DE60234085D1 DE60234085T DE60234085T DE60234085D1 DE 60234085 D1 DE60234085 D1 DE 60234085D1 DE 60234085 T DE60234085 T DE 60234085T DE 60234085 T DE60234085 T DE 60234085T DE 60234085 D1 DE60234085 D1 DE 60234085D1
Authority
DE
Germany
Prior art keywords
hepatitis
compound interferon
recombinant super
antigen inhibitor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234085T
Other languages
English (en)
Inventor
Guangwen Wei
Rongbing Guo
Renhuai Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SICHUAN BIOTECHNOLOGY RES CT C
Original Assignee
SICHUAN BIOTECHNOLOGY RES CT C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SICHUAN BIOTECHNOLOGY RES CT C filed Critical SICHUAN BIOTECHNOLOGY RES CT C
Application granted granted Critical
Publication of DE60234085D1 publication Critical patent/DE60234085D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE60234085T 2001-02-28 2002-02-28 Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor Expired - Lifetime DE60234085D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB011043679A CN1245215C (zh) 2001-02-28 2001-02-28 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
PCT/CN2002/000128 WO2002080958A1 (fr) 2001-02-28 2002-02-28 Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b

Publications (1)

Publication Number Publication Date
DE60234085D1 true DE60234085D1 (de) 2009-12-03

Family

ID=4653854

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234085T Expired - Lifetime DE60234085D1 (de) 2001-02-28 2002-02-28 Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor

Country Status (10)

Country Link
US (3) US7364724B2 (de)
EP (1) EP1371373B1 (de)
JP (1) JP4617058B2 (de)
CN (1) CN1245215C (de)
AT (1) ATE446104T1 (de)
AU (1) AU2003248419B2 (de)
CA (1) CA2439503A1 (de)
DE (1) DE60234085D1 (de)
HK (1) HK1061201A1 (de)
WO (1) WO2002080958A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
US7335496B2 (en) * 2003-06-05 2008-02-26 Ajinomoto Co., Inc. Method for producing target substance
AU2011202683B2 (en) * 2003-08-28 2012-08-09 Superlab Far East Limited Uses of interferons with altered spatial structure
DK1663110T3 (en) * 2003-08-28 2014-03-24 Superlab Far East Ltd APPLICATIONS OF INTERFERONES WITH CHANGED SPACIAL STRUCTURE
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
CA2535982C (en) * 2003-08-28 2016-11-29 Huiyangtech (Usa), Inc. Uses of interferons with altered spatial structure
CN1740197B (zh) * 2004-08-26 2010-05-12 辉阳科技美国公司 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
MY167668A (en) * 2005-03-09 2018-09-21 Superlab Far East Ltd Uses of recombinant super-compound interferons
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
CN102101886A (zh) * 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
WO2013055811A1 (en) * 2011-10-12 2013-04-18 Hitachi Chemical Co., Ltd. Ex vivo methods of predicting responsiveness of a subject to interferon therapy
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
EP2583677A3 (de) 2011-10-21 2013-07-03 Abbvie Inc. Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
TWI718086B (zh) * 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
CA2929893C (en) 2013-11-13 2023-03-14 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
KR102561720B1 (ko) 2015-05-12 2023-07-28 수퍼랩 파 이스트 리미티드 종양에 대한 직접적인 억제 효과를 갖는 인터페론의 결정 방법 및 그 용도
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
NZ202698A (en) 1981-12-07 1986-02-21 Hoffmann La Roche Human leukocyte interferon in crystalline form
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4681930A (en) 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
EP0626448A3 (de) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
DE4329756A1 (de) 1993-09-03 1995-03-09 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CA2232230C (en) 1995-10-13 2005-06-28 Ralph H. Lambalot Phosphopantetheinyl transferases and uses thereof
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6532437B1 (en) 1996-10-23 2003-03-11 Cornell Research Foundation, Inc. Crystalline frap complex
CN1186120A (zh) 1996-12-24 1998-07-01 深圳科兴生物制品有限公司 在大肠杆菌中表达作为分泌的重组人干扰素α1b蛋白
WO1999029862A1 (en) * 1997-12-05 1999-06-17 Human Genome Sciences, Inc. Synferon, a synthetic type i interferon
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
BR9907964A (pt) 1998-02-06 2000-10-17 Ilexus Pty Limited Estruturas tridimensionais e modelos de receptores fc e usos dos mesmos
CN1062565C (zh) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 重组人α型复合干扰素及其制备方法和用途
KR100399156B1 (ko) 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US20020043262A1 (en) * 2000-08-22 2002-04-18 Alan Langford Spray device
US7544354B2 (en) * 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
AU2888602A (en) 2000-11-03 2002-05-15 Pbl Biomedical Lab Interferons, uses and compositions related thereto
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US6546074B1 (en) 2001-03-27 2003-04-08 Astex Technology Limited Protein crystal structure and method for identifying protein modulators
CN1375502A (zh) 2001-10-25 2002-10-23 南京药科大学 聚乙二醇修饰重组人干扰素
US6807478B2 (en) * 2001-12-27 2004-10-19 Koninklijke Philips Electronics N.V. In-building navigation system
CN1176946C (zh) 2002-05-16 2004-11-24 中国人民解放军第二军医大学 一种新型α干扰素
CN1202861C (zh) 2003-07-18 2005-05-25 中国科学院微生物研究所 复合干扰素在治疗sars疾病中的用途
CA2535982C (en) 2003-08-28 2016-11-29 Huiyangtech (Usa), Inc. Uses of interferons with altered spatial structure
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
MY167668A (en) 2005-03-09 2018-09-21 Superlab Far East Ltd Uses of recombinant super-compound interferons

Also Published As

Publication number Publication date
US7364724B2 (en) 2008-04-29
JP4617058B2 (ja) 2011-01-19
HK1061201A1 (en) 2004-09-10
EP1371373A4 (de) 2005-05-04
JP2005508848A (ja) 2005-04-07
US20080305080A1 (en) 2008-12-11
US20110189128A1 (en) 2011-08-04
EP1371373B1 (de) 2009-10-21
US8114395B2 (en) 2012-02-14
EP1371373A1 (de) 2003-12-17
CN1245215C (zh) 2006-03-15
AU2003248419B2 (en) 2007-01-04
CN1311035A (zh) 2001-09-05
WO2002080958A1 (fr) 2002-10-17
ATE446104T1 (de) 2009-11-15
AU2003248419A1 (en) 2003-11-06
US8425896B2 (en) 2013-04-23
CA2439503A1 (en) 2002-10-17
US20040202641A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
DE60234085D1 (de) Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
ES2523837T3 (es) Agentes de unión específica al factor de crecimiento de hepatocitos
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
DK1476541T3 (da) Cytokin (zcytor17-ligand)
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
DE60131456D1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
DK1261723T3 (da) Hybrid ekspression af Neisseria-proteiner
ATE390441T1 (de) Niedrigallergene proteinvarianten
FR20C1016I1 (de)
DE60138014D1 (de) Chimäre arterivirus-ähnliche partikel
CY1111750T1 (el) Νευροτροφικοι παραγοντες
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
LU92748I2 (fr) Virus de la diarrhée virale bovine atténué 2 (bvdv-2)
DE60207053D1 (de) Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
ATE313558T1 (de) Reinigung von hbv-antigenen zur verwendung in impfstoffen
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
DK1501936T3 (da) Familie af cytokin-proteiner
ATA192799A (de) Neue verwendung von antikörpern als impfstoffe
ATE473997T1 (de) Zur bildung von partikeln fähiges hbv-precore- protein
DE60115938D1 (de) Monoklonale antikörper gegen hepatitis b virus
ATE320266T1 (de) Induktion von antigen-spezifischen t-zellen durch interferon
EP1310512A3 (de) HCV-Kernprotein-Sequenzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition